CTOs on the Move

TBS Dental

www.tbsdental.com

 
We create premium products to make dentistry more efficient. Over the years, TBS has designed and developed a number of contemporary, state-of-the-art instruments with the intent of modernization.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.

EZ-MED

EZ-MED is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Recor Medical

The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...

miraDry

Make excessive sweat a thing of the past. Learn how miraDry® can permanently reduce underarm sweat in as little as one non-surgical treatment.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.